Germany-based drugs group Merck Ventures now manages $340m.

The initial public offering on Aim will provide an exit to shareholders including Novartis, which gave Mereo access to three of its clinical stage therapies last year.

Oncology-focused big data platform provider Sipai Wangluo has reportedly received tens of millions of US dollars from investors including Ping An Insurance.

Santen-backed Clearside Biomedical, which had raised some $48m in funding, is offering 7.2 million shares on Nasdaq priced at $7 each.

The personalised healthcare subsidiary of NantWorks, backed by Celgene, Blackberry and Allscripts, has priced its initial public offering at $14 a share.

Corporate-backed EarlySense has closed a $25m funding round led by financial services firm Bank Hapoalim and backed by a range of existing investors.

Following the opening of the UK's first proton beam treatment centre in 2018 or 2019, Imperial College London and the centre will commence a $17m research partnership.

Prescription services platform 1mg has raised an undisclosed amount from HBM Healthcare Investments a month after securing $15m in series B funding.